<DOC>
	<DOCNO>NCT00002846</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill kidney cancer cell . PURPOSE : Phase II trial study effectiveness low-dose interleukin-2 treating patient metastatic recurrent kidney cancer .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Metastatic Recurrent Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess response rate survival patient metastatic renal cell carcinoma treat low-dose intravenous interleukin-2 . - Assess toxicity associate treatment . OUTLINE : Patients receive low-dose intravenous interleukin-2 every 8 hour maximum 15 dos week 1 week 3 . Stable respond patient receive second course begin approximately 2 month initiation first course . Responding patient may continue therapy every 2 month provide toxicity limit . Patients whose diseased kidney comprises bulk tumor burden entry undergo nephrectomy . Patients follow survival . PROJECTED ACCRUAL : A total 14 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma ( RCC ) metastatic recurrent No central nervous system major nerve involvement No 25 % estimate hepatic replacement tumor CT MRI Measurable disease require PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80 % 100 % Life expectancy : Greater 3 month Hematopoietic : Platelet count least 80,000/mm3 Hepatic : Bilirubin normal AST ALT great 3 time normal Renal : Creatinine normal Cardiovascular : Stress cardiac exam normal ( exam perform patient age 50 old potential cardiac disease suggest history , physical exam , EKG ) Pulmonary : FEV1 VC great 65 % predict ( test perform patient significant smoke history potential pulmonary disease suggest history , physical exam , xray ) Other : No site ongoing bleed No HIV antibody AIDS No hepatitis B antigen No systemic infection No requirement steroids No psychiatric disease precludes inform consent safe administration immunotherapy No second malignancy except : Basal cell carcinoma In situ cervical cancer Other cancer provide evaluable lesion document RCC No pregnant nursing woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy No prior interleukin2 therapy Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 28 day since therapy RCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>